Negative symptoms in schizophrenia - the remarkable impact of inclusion definitions in clinical trials and their consequences

Schizophrenia Research

Volumn 150, Issue 2-3, 2013, Pages 334-338

  Rabinowitz, Jonathan ^a   Werbeloff, Nomi ^a   Caers, Ivo ^b   Mandel, Francine S ^c   Stauffer, Virginia ^d   Menard, François ^e   Kinon, Bruce J ^d   Kapur, Shitij ^f  

^a BAR ILAN UNIVERSITY   (Israel)

^b JANSSEN RESEARCH AND DEVELOPMENT   (Belgium)

^c PFIZER INC   (United States)

^d ELI LILLY AND COMPANY   (United States)

^e Lundbeck   (France)

^f KING'S COLLEGE LONDON   (United Kingdom)

Author keywords

Antipsychotic trials; Negative symptoms

Indexed keywords

NEUROLEPTIC AGENT; PLACEBO;

ARTICLE; CLINICAL DATA REPOSITORY; CLINICAL EFFECTIVENESS; CLINICAL TRIAL (TOPIC); CONTROLLED CLINICAL TRIAL (TOPIC); CONTROLLED STUDY; DISEASE EXACERBATION; DISEASE SEVERITY; DRUG EFFICACY; HUMAN; MAJOR CLINICAL STUDY; NEGATIVE SYNDROME; PATIENT SELECTION; PRIORITY JOURNAL; SCHIZOPHRENIA; TREATMENT DURATION; TREATMENT OUTCOME;

ANTIPSYCHOTIC TRIALS; NEGATIVE SYMPTOMS;

ANTIPSYCHOTIC AGENTS; CLINICAL TRIALS AS TOPIC; DATABASES, FACTUAL; HUMANS; PATIENT SELECTION; SCHIZOPHRENIA; SCHIZOPHRENIC PSYCHOLOGY; TREATMENT OUTCOME;

EID: 84886292415     PISSN: 09209964     EISSN: 15732509     Source Type: Journal    
DOI: 10.1016/j.schres.2013.06.023     Document Type: Article

References (13)

1. Berman I., Viegner B., Merson A., Allan E., Pappas D., Green A.I. Differential relationships between positive and negative symptoms and neuropsychological deficits in schizophrenia. Schizophr. Res. 1997, 25(1):1-10.
2. Emsley R.A., Rabinowitz J., Torreman M. The factor structure for the Positive and Negative Syndrome Scale (PANSS) in recent-onset psychosis. Schizophr. Res. 2003, 61(1):47-57.
3. European Medicines Agency Guideline on clinical investigation of medicinal products, including depot preparations in the treatment of schizophrenia. Committee for Medicinal Products for Human Use (CHMP) 2012, 18. European Medicines Agency, London.
4. Kinon B.J., Noordsy D.L., Liu-Seifert H., Gulliver A.H., Ascher-Svanum H., Kollack-Walker S. Randomized, double-blind 6-month comparison of olanzapine and quetiapine in patients with schizophrenia or schizoaffective disorder with prominent negative symptoms and poor functioning. J. Clin. Psychopharmacol. 2006, 26(5):453-461.
5. Kirkpatrick B., Fenton W.S., Carpenter W.T., Marder S.R. The NIMH-MATRICS consensus statement on negative symptoms. Schizophr. Bull. 2006, 32(2):214-219.
6. Laughren T., Levin R. Food and Drug Administration perspective on negative symptoms in schizophrenia as a target for a drug treatment claim. Schizophr. Bull. 2006, 32(2):220-222.
7. Laughren T., Levin R. Food and Drug Administration commentary on methodological issues in negative symptom trials. Schizophr. Bull. 2011, 37(2):255-256.
8. Moller H.J., Riedel M., Muller N., Fischer W., Kohnen R. Zotepine versus placebo in the treatment of schizophrenic patients with stable primary negative symptoms: a randomized double-blind multicenter trial. Pharmacopsychiatry 2004, 37(6):270-278.
9. Olie J.P., Spina E., Murray S., Yang R. Ziprasidone and amisulpride effectively treat negative symptoms of schizophrenia: results of a 12-week, double-blind study. Int. Clin. Psychopharmacol. 2006, 21(3):143-151.
10. Rabinowitz J., Levine S.Z., Garibaldi G., Bugarski-Kirola D., Berardo C.G., Kapur S. Negative symptoms have greater impact on functioning than positive symptoms in schizophrenia: analysis of CATIE data. Schizophr. Res. 2012, 137(1-3):147-150.
11. Riedel M., Muller N., Strassnig M., Spellmann I., Engel R.R., Musil R., Dehning S., Douhet A., Schwarz M.J., Moller H.J. Quetiapine has equivalent efficacy and superior tolerability to risperidone in the treatment of schizophrenia with predominantly negative symptoms. Eur. Arch. Psychiatry Clin. Neurosci. 2005, 255(6):432-437.
12. Stauffer V.L., Song G., Kinon B.J., Ascher-Svanum H., Chen L., Feldman P.D., Conley R.R. Responses to antipsychotic therapy among patients with schizophrenia or schizoaffective disorder and either predominant or prominent negative symptoms. Schizophr. Res. 2012, 134(2-3):195-201.
13. Ventura J., Nuechterlein K.H., Green M.F., Horan W.P., Subotnik K.L., Mintz J. The timing of negative symptom exacerbations in relationship to positive symptom exacerbations in the early course of schizophrenia. Schizophr. Res. 2004, 69(2-3):333-342.